scientific reports



OPEN Author Correction: Antidepressants during and after Menopausal **Transition: A Systematic Review** and Meta-Analysis

Published online: 30 August 2022

Ching-Kuan Wu, Ping-Tao Tseng, Ming-Kung Wu, Dian-Jeng Li, Tien-Yu Chen, Fu-Chen Kuo, Brendon Stubbs, Andre F. Carvalho, Yen-Wen Chen, Pao-Yen Lin, Yu-Shian Cheng & Cheuk-Kwan Sun

Correction to: Scientific Reports https://doi.org/10.1038/s41598-020-64910-8, published online 15 May 2020

The original version of this Article contained errors.

In Figure 2, the data corresponding to the low-dose Desvenlafaxine (100 mg/day) and high-dose Desvenlafaxine (150 mg/day) treatment arms of Cheng, 2013 were not labelled. The original Figure 2 and accompanying legend appear below.

Additionally, in the Methods section, under the sub-heading 'Guidelines and protocol',

"This systematic review and meta-analysis was conducted according to the guidelines presented in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement¹⁸ (Supplementary Table S1). An a priori defined but unpublished protocol (available upon request to the authors) that was approved by the Institutional Review Board of Tri-Service General Hospital (TSGHIRB: B-105-12) was followed."

now reads:

"This systematic review and meta-analysis was conducted according to the guidelines presented in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement¹⁸ (Supplementary Table S1)."

The study protocol is reported in detail in the Methods section of the Article.

The original Article has been corrected.

Hedges' Lower Upper g Povalue Povalue Povalue Povalue Relative Weight Davari-Tanha, 2016 ²⁹ No Venlafaxine SNRI 0.80 0.17 1.43 0.01 3.47 Davari-Tanha, 2016 ²⁹ No Citalopram SSRI 0.28 -0.33 0.89 0.36 3.70 Macias-Cortes, 2015 ¹² Yes Fluoxetine SSRI 0.86 0.43 1.29 0.00 6.65 Clayton, 2013 ¹¹ Yes Desvenlafaxine SNRI 0.28 0.10 0.47 0.00 18.58 Cheng, 2013 ¹⁶ Exclude Desvenlafaxine SNRI 0.38 0.15 0.61 0.00 15.66 Kornstein, 2010 ³⁰ Yes Desvenlafaxine SNRI 0.63 0.41 0.85 0.00 16.20 Soares, 2008 ³¹ Exclude Paroxetine SSRI 0.70 0.17 1.24 0.01 4.69 Suvanto-Luukkonen, 2005 ¹⁷ Exclude Citalopram SSRI 0.26 -0.13 0.64 0.20	Author, year Ref	MDD	Medication (n Classification		Statistics of each stud			udy	dy Hedges'			95% CI	
Davari-Tanha, 2016 ²⁹ No Citalopram SSRI 0.28 -0.33 0.89 0.36 3.70 Macias-Cortes, 2015 ¹² Yes Fluoxetine SSRI 0.86 0.43 1.29 0.00 6.65 Clayton, 2013 ¹¹ Yes Desvenlafaxine SNRI 0.28 0.10 0.47 0.00 18.58 Cheng, 2013 ¹⁶ Exclude Desvenlafaxine SNRI 0.38 0.15 0.61 0.00 15.66 Kornstein, 2010 ³⁰ Yes Desvenlafaxine SNRI 0.63 0.41 0.85 0.00 16.20 Soares, 2008 ³¹ Exclude Paroxetine SSRI 0.70 0.17 1.24 0.01 4.69 Suvanto-Luukkonen, 2005 ¹⁷ Exclude Citalopram SSRI 0.26 -0.13 0.65 0.19 7.68					Hedges	' Lower limit	Upper limit	<i>p</i> -value	Relative weight					
Macias-Cortes, 2015 12 Yes Fluoxetine SSRI 0.86 0.43 1.29 0.00 6.65 Clayton, 2013 11 Yes Desvenlafaxine SNRI 0.28 0.10 0.47 0.00 18.58 Cheng, 2013 16 Exclude Desvenlafaxine SNRI 0.38 0.15 0.61 0.00 15.66 Cheng, 2013 16 Exclude Desvenlafaxine SNRI 0.38 0.15 0.61 0.00 15.63 Kornstein, 2010 30 Yes Desvenlafaxine SNRI 0.63 0.41 0.85 0.00 16.20 Soares, 2008 31 Exclude Paroxetine SSRI 0.70 0.17 1.24 0.01 4.69 Suvanto-Luukkonen, 2005 17 Exclude Citalopram SSRI 0.26 -0.13 0.65 0.19 7.68 Suvanto-Luukkonen, 2005 17 Exclude Fluoxetine SSRI 0.25 -0.14 0.64 0.20 7.74	Davari-Tanha, 2016 ²⁹	No	Venlafaxine	SNRI	0.80	0.17	1.43	0.01	3.47				+	
Clayton, 2013 11 Yes Desvenlafaxine SNRI 0.28 0.10 0.47 0.00 18.58 Cheng, 2013 16 Exclude Desvenlafaxine SNRI 0.38 0.15 0.61 0.00 15.66 Cheng, 2013 16 Exclude Desvenlafaxine SNRI 0.38 0.15 0.61 0.00 15.63 Kornstein, 2010 30 Yes Desvenlafaxine SNRI 0.63 0.41 0.85 0.00 16.20 Soares, 2008 31 Exclude Paroxetine SSRI 0.70 0.17 1.24 0.01 4.69 Suvanto-Luukkonen, 2005 17 Exclude Citalopram SSRI 0.26 -0.13 0.65 0.19 7.68 Suvanto-Luukkonen, 2005 17 Exclude Fluoxetine SSRI 0.25 -0.14 0.64 0.20 7.74	Davari-Tanha, 2016 ²⁹	No	Citalopram	SSRI	0.28	-0.33	0.89	0.36	3.70			+		
Cheng, 2013 ¹⁶ Exclude Desvenlafaxine SNRI 0.38 0.15 0.61 0.00 15.66 Cheng, 2013 ¹⁶ Exclude Desvenlafaxine SNRI 0.38 0.15 0.61 0.00 15.63 Kornstein, 2010 ³⁰ Yes Desvenlafaxine SNRI 0.63 0.41 0.85 0.00 16.20 Soares, 2008 ³¹ Exclude Paroxetine SSRI 0.70 0.17 1.24 0.01 4.69 Suvanto-Luukkonen, 2005 ¹⁷ Exclude Citalopram SSRI 0.26 -0.13 0.65 0.19 7.68 Suvanto-Luukkonen, 2005 ¹⁷ Exclude Fluoxetine SSRI 0.25 -0.14 0.64 0.20 7.74	Macias-Cortes, 2015 ¹²	Yes	Fluoxetine	SSRI	0.86	0.43	1.29	0.00	6.65			.	-	
Cheng, 2013 ¹⁶ Exclude Desvenlafaxine SNRI 0.38 0.15 0.61 0.00 15.63 Kornstein, 2010 ³⁰ Yes Desvenlafaxine SNRI 0.63 0.41 0.85 0.00 16.20 Soares, 2008 ³¹ Exclude Paroxetine SSRI 0.70 0.17 1.24 0.01 4.69 Suvanto-Luukkonen, 2005 ¹⁷ Exclude Citalopram SSRI 0.26 -0.13 0.65 0.19 7.68 Suvanto-Luukkonen, 2005 ¹⁷ Exclude Fluoxetine SSRI 0.25 -0.14 0.64 0.20 7.74	Clayton, 2013 ¹¹	Yes	Desvenlafaxine	s SNRI	0.28	0.10	0.47	0.00	18.58			1		
Kornstein, 2010 30 Yes Desvenlafaxine SNRI 0.63 0.41 0.85 0.00 16.20 Soares, 2008 31 Exclude Paroxetine SSRI 0.70 0.17 1.24 0.01 4.69 Suvanto-Luukkonen, 2005 17 Exclude Citalopram SSRI 0.26 -0.13 0.65 0.19 7.68 Suvanto-Luukkonen, 2005 17 Exclude Fluoxetine SSRI 0.25 -0.14 0.64 0.20 7.74	Cheng, 2013 ¹⁶	Exclude	Desvenlafaxine	SNRI	0.38	0.15	0.61	0.00	15.66			-	-	
Soares, 2008 31 Exclude Paroxetine SSRI 0.70 0.17 1.24 0.01 4.69 Suvanto-Luukkonen, 2005 17 Exclude Citalopram SSRI 0.26 -0.13 0.65 0.19 7.68 Suvanto-Luukkonen, 2005 17 Exclude Fluoxetine SSRI 0.25 -0.14 0.64 0.20 7.74	Cheng, 2013 ¹⁶	Exclude	Desvenlafaxine	SNRI	0.38	0.15	0.61	0.00	15.63			-	-	
Suvanto-Luukkonen, 2005 17 Exclude Citalopram SSRI 0.26 -0.13 0.65 0.19 7.68 Suvanto-Luukkonen, 2005 17 Exclude Fluoxetine SSRI 0.25 -0.14 0.64 0.20 7.74	Kornstein, 2010 ³⁰	Yes	Desvenlafaxine	SNRI	0.63	0.41	0.85	0.00	16.20			-	-	
Suvanto-Luukkonen, 2005 ¹⁷ Exclude Fluoxetine SSRI 0.25 -0.14 0.64 0.20 7.74	Soares, 2008 ³¹	Exclude	Paroxetine	SSRI	0.70	0.17	1.24	0.01	4.69					
T [®] T	Suvanto-Luukkonen, 2005 ¹⁷	Exclude	Citalopram	SSRI	0.26	-0.13	0.65	0.19	7.68			4	-	
Overall 0.44 0.32 0.57 0.00 100.00	Suvanto-Luukkonen, 2005 ¹⁷	Exclude	Fluoxetine	SSRI	0.25	-0.14	0.64	0.20	7.74			4	-	
	Overall				0.44	0.32	0.57	0.00	100.00			1		
-2.00 -1.00 0.00										-2.00	-1.00	0.00	1.00	2.00

Figure 2. Forest plot of changes in depressive symptoms in menopausal women with antidepressant treatments compared to those without. Note significantly better improvements in severity of depressive symptoms (k = 10, Hedges' g = 0.44, 95% CI 0.32 to 0.57, p < 0.001) in subjects receiving antidepressants compared to that in controls.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022